Featured

Merger Law Is Dante’s Inferno Revisited

Merger Law Is Dante’s Inferno Revisited

The shift by agencies away from the current guidelines on mergers and acquisitions has left firms in limbo.

Week in Review

Week in Review

U.S. senators introduce the RESTRICT Act, Tennessee governor bans drag shows in public places, and more…

Creating a Safe Testing Space for High-Risk AI

Creating a Safe Testing Space for High-Risk AI

Scholars argue for the creation of a regulatory safe space to supplement AI regulations.

CFPB Targets Illegal Junk Fees

CFPB Targets Illegal Junk Fees

New CFPB guidance puts banks on notice that unfair business practices may be met with enforcement action.

Fighting Fires Through Resilience Regulation

Fighting Fires Through Resilience Regulation

Scholars identify wildfire resilience solutions for the power sectors in California and Australia.

Jimmy Carter, The Great Deregulator

Jimmy Carter, The Great Deregulator

By pushing for deregulation and adopting other reforms, President Carter left an enduring legacy on the U.S. regulatory system.

How to Shelter Homeless Youth

How to Shelter Homeless Youth

Scholars examine regulatory solutions to combat youth homelessness.

Week in Review

Week in Review

A federal judge rules that Texas cannot prosecute organizations that facilitate abortion access, the DEA proposes rules expanding telemedicine care, and more…

New NCAA Rules Leave Foreign Student-Athletes Behind

New NCAA Rules Leave Foreign Student-Athletes Behind

Scholars argue that foreign student-athletes must now choose between earning money and keeping their immigration status.

FDA, Not a Federal Judge, Should Decide on Abortion Drugs

FDA, Not a Federal Judge, Should Decide on Abortion Drugs

Anti-abortion advocates take aim at FDA approval and regulation of the abortion drug mifepristone, threatening access nationwide.

Is Your Phone a Medical Device?

Is Your Phone a Medical Device?

Scholar argues that Congress and FDA should treat risky clinical artificial intelligence tools as medical devices.

FDA Advances Program for Real-World Evidence

FDA Advances Program for Real-World Evidence

FDA’s approach to evidence-based decision-making may not be addressed to the right people.